Skip to main content

Alembic gets tentative FDA nod for generic Brilinta tablets

Alembic Pharmaceuticals recently received tentative approval from the Food and Drug Administration for a generic of Astrazeneca’s Briinta (ticagrelor) tablets in a 90-mg dosage strength.

Ticagrelor tablets are indicated to reduce the rate of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction.

The product has a market value of approximately $625 million for the 12 months ended December 2017, according to IQVIA.
This ad will auto-close in 10 seconds